Stock Events

Stock Events

GenSight Biologics. 

$0.19
31
+$0+0% Monday 21:00

Statistics

Day High
0.45
Day Low
0.45
52W High
0.45
52W Low
0.19
Volume
756
Avg. Volume
1
Mkt Cap
24.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27MarExpected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q2 2025
Next
-0.07
-0.04
-0.02
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-928.41%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
3.14MRevenue
-29.2MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GSGTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, some of which overlap with GenSight's target indications.
The Nightview Fund NITE
NITE
Mkt Cap0
Nightstar Therapeutics was acquired by Biogen and focuses on gene therapy for inherited retinal disorders, directly competing with GenSight.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on CRISPR gene editing, a technology that could be applied to similar diseases as GenSight's gene therapy approach.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, potentially targeting the same genetic eye diseases as GenSight.
Abeona Therapeutics
ABEO
Mkt Cap246.65M
Abeona Therapeutics develops gene and cell therapies for serious diseases, including ophthalmological conditions, competing in GenSight's domain.

About

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Show more...
CEO
Ms. Laurence Rodriguez
Employees
16
Country
FR
ISIN
FR0013183985

Listings

F
DE
G49N.F
LSE
GB
0RIM.LSE
OTC Link
US
GSGTF
PA
FR
SIGHT.PA

0 Comments

Share your thoughts

FAQ

What is GenSight Biologics. stock price today?▼
The current price of GSGTF is $0.19 USD — it has increased by +0% in the past 24 hours. Watch GenSight Biologics. stock price performance more closely on the chart.
What is GenSight Biologics. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GenSight Biologics. stocks are traded under the ticker GSGTF.
What is GenSight Biologics. market cap?▼
Today GenSight Biologics. has the market capitalization of 24.99M
When is the next GenSight Biologics. earnings date?▼
GenSight Biologics. is going to release the next earnings report on July 23, 2026.
What is GenSight Biologics. revenue for the last year?▼
GenSight Biologics. revenue for the last year amounts to 3.14M USD.
What is GenSight Biologics. net income for the last year?▼
GSGTF net income for the last year is -29.2M USD.
How many employees does GenSight Biologics. have?▼
As of April 01, 2026, the company has 16 employees.
In which sector is GenSight Biologics. located?▼
GenSight Biologics. operates in the Health Care sector.
When did GenSight Biologics. complete a stock split?▼
GenSight Biologics. has not had any recent stock splits.
Where is GenSight Biologics. headquartered?▼
GenSight Biologics. is headquartered in Paris, FR.